# Impact of Introducing a Multiplex Polymerase Chain Reaction Blood Culture Panel on Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) and Carbapenem Antimicrobial Agents in a Children’s Hospital

**Authors:** Kenta Kuruma, Hanako Funakoshi, Meiwa Shibata, Keiko Okita, Junichi Suwa, Tomoyuki Tame, Yuho Horikoshi

PMC · DOI: 10.7759/cureus.66282 · 2024-08-06

## TL;DR

Using a fast DNA test in blood cultures reduced the use of specific antibiotics for a type of bacteria in children but not for others.

## Contribution

The study shows that multiplex PCR reduces anti-MRSA antimicrobial use in pediatric bacteremia cases.

## Key findings

- Anti-MRSA antimicrobial use decreased from 73% to 49% after introducing multiplex PCR.
- Carbapenem use for gram-negative rod bacteremia remained unchanged.
- No vancomycin or carbapenem resistance genes were detected in the study periods.

## Abstract

Background: With the advent of multiplex polymerase chain reaction (PCR) using samples from a positive blood culture, the time required to identify a pathogen has significantly shortened to a few hours. It can help us select appropriate antimicrobial agents more quickly. The present study aimed to assess the impact of using a multiplex PCR blood culture panel on the appropriate administration of antimicrobial agents.

Methods: Patients aged <16 years with culture-confirmed bacteremia at Tokyo Metropolitan Children's Medical Center were enrolled. A pre-intervention period (period I: December 2016 to December 2018) and a post-intervention period with multiplex PCR use for the confirmation of positive blood cultures (period II: December 2019 to December 2021) were compared for their effect on the use of antimicrobial agents for gram-positive cocci (GPC) and gram-negative rod (GNR) bacteremia. Data on patient background, blood culture results, and antimicrobial use were retrospectively collected from electronic medical records.

Results: Periods I and II had 174 and 154 patients, respectively. The median age at periods I and II was 14 (IQR 2-82) months and 12 (IQR 1-78) months, respectively. GPC bacteremia during periods I and II occurred in 140 and 115 patients, respectively. GNR during periods I and II occurred in 34 and 39 patients, respectively. Neither the vancomycin-resistance genes A/B nor the carbapenem-resistance gene were detected. The use of antimicrobial agents against anti-methicillin-resistant Staphylococcus aureus (MRSA) for GPC bacteremia decreased from 103/140 cases (73%) in period I to 56/115 cases (49%) in period II (p=0.047). The use of carbapenems for GNR bacteremia did not change significantly, at 23/34 (68%) in period I and 34/39 (87%) in period II (p=0.47).

Conclusion: Introducing multiplex PCR for pediatric bacteremia decreased the use of anti-MRSA antimicrobial agents but not of carbapenems.

## Linked entities

- **Chemicals:** vancomycin (PubChem CID 14969), carbapenems (PubChem CID 134085)
- **Diseases:** bacteremia (MONDO:0005229)
- **Species:** Staphylococcus aureus (taxon 1280)

## Full-text entities

- **Diseases:** bacteremia (MESH:D016470), GPC (MESH:D016908), GNR (MESH:D016905)
- **Species:** Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280]

---
Source: https://tomesphere.com/paper/PMC11376315